• Organizations: RegenxBio
RegenxBio reports positive phase 2 bilateral wet AMD data
Pipeline

RegenxBio reports positive phase 2 bilateral wet AMD data

Nine-month clinical findings noted a 97% reduction in treatment burden following subretinal delivery of gene therapy treatment.
REGENXBIO shares 2-year data on gene therapy injection for wet AMD
Pipeline

REGENXBIO shares 2-year data on gene therapy injection for wet AMD

Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.
RegenxBio reports positive interim data in gene therapy trial for wet AMD
Pipeline

RegenxBio reports positive interim data in gene therapy trial for wet AMD

Phase 2 AAVIATE study is evaluating ABBV-RGX-314 as a one-time, subretinal injection.
Positive 1-year data reported in ALTITUDE gene therapy trial
Pipeline

Positive 1-year data reported in ALTITUDE gene therapy trial

Ongoing phase 2 trial reports potential for one-time injection in managing DR.
RegenxBio to globally expand pivotal trials for wet AMD gene therapy
Pipeline

RegenxBio to globally expand pivotal trials for wet AMD gene therapy

Company shares updates on development and commercialization plans for ABBV-RGX-314.